Direct Molecular Detection of Drug-Resistant Tuberculosis from Transported Bio-Safe Dried Sputum on Filter-Paper
Authors:
- Shaina JamwalSJShaina Jamwal
- Rakesh Kumar GuptaRGRakesh Kumar Gupta
- Ritu SinghalRSRitu Singhal
- Ajoy Kumar VermaAVAjoy Kumar Verma
- Manpreet BhallaMBManpreet Bhalla
- Vithal Prasad MyneeduVMVithal Prasad Myneedu
- Sangeeta ChoudharySCSangeeta Choudhary
- Jaya Sivaswami TyagiJTJaya Sivaswami Tyagi
- Sagarika HaldarSHSagarika Haldar
- 17 February 2022
- journal article
- research article
- Published by Springer Nature in Current Microbiology
- Vol. 79 (4) , 1-9
Abstract
In 2019, amongst half a million new rifampicin-resistant tuberculosis (TB) cases, 78% were multi drug-resistant TB (MDR-TB). Access to rapid and Universal-Drug susceptibility testing (DST) to patients in remote areas is a major challenge to combat drug-resistant TB. To overcome this challenge, we had recently reported the development of ‘TB Concentration & Transport kit’ for bio-safe ambient temperature transport of dried sputum on filter-paper (Trans-Filter). The present study was conducted to evaluate the utility of DNA extracted from sputum on Trans-Filter in a Multiplex PCR-based sequencing assay (Mol-DSTseq) for diagnosing drug-resistant TB. The developed Mol-DSTseq assays were standardized on Mycobacterium tuberculosis clinical isolates (n = 98) and further validated on DNA extracted from sputum on Trans-Filter (n = 100). Using phenotypic DST as gold standard, the Mol-DSTseq assay showed 100% (95% Confidence Interval [CI] 79.4–100%) and 73.3% (95% CI 54.1–87.7%) sensitivity for detecting rifampicin and isoniazid resistance with a specificity of 85.1% (95% CI 66.2–95.8%) and 100% (95% CI:82.3–100%), respectively. For fluoroquinolones and aminoglycosides, the Mol-DSTseq assay showed a sensitivity of 78.5% (95% CI 49.2–95.3%) and 66.6% (95% CI 9.4–99.1%) with a specificity of 88.2% (95% CI 72.5–96.7%) and 100% (95% CI 93.1–100%), respectively. The Mol-DSTseq assays exhibited a high concordance of ~ 83–96% (κ value: 0.65–0.81) with phenotypic DST for all drugs. In conclusion, the ‘TB Concentration and Transport kit’ was compatible with Mol-DSTseq assays and has the potential to provide ‘Universal-DST’ to patients residing in distant areas in high burden countries, like India for early initiation of anti-tubercular treatment.Keywords
Funding Information
- PGIMER, Chandigarh (Intramural Grant-71/2-Edu-16/4465)
This publication has 19 references indexed in Scilit:
- Detection of First-Line Drug Resistance Mutations and Drug–Protein Interaction Dynamics from Tuberculosis Patients in South IndiaMicrobial Drug Resistance, 2018
- Applied multiplex allele specific PCR to detect second-line drug resistance among multidrug-resistant tuberculosis in ChinaTuberculosis, 2017
- Evaluation of a Rapid Molecular Drug-Susceptibility Test for TuberculosisNew England Journal of Medicine, 2017
- Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic ReviewPLOS ONE, 2015
- Molecular Diagnosis of Fluoroquinolone Resistance in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2015
- Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarraysBMC Infectious Diseases, 2013
- Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing ofMycobacterium tuberculosisTuberculosis Research and Treatment, 2013
- Rapid Identification of Mycobacteria and Drug-Resistant Mycobacterium tuberculosis by Use of a Single Multiplex PCR and DNA SequencingJournal of Clinical Microbiology, 2012
- New Multiplex PCR for Rapid Detection of Isoniazid-Resistant Mycobacterium tuberculosis Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2005
- Molecular genetic basis of antimicrobial agent resistance inMycobacterium tuberculosis: 1998 updateTubercle and Lung Disease, 1998